NeuBase Therapeutics Inc
F:O7PA
NeuBase Therapeutics Inc
Net Income
NeuBase Therapeutics Inc
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NeuBase Therapeutics Inc
F:O7PA
|
Net Income
-$13.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-9%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income
$2.4B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income
$3.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income
$4.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
22%
|
|
NeuBase Therapeutics Inc
Glance View
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
See Also
What is NeuBase Therapeutics Inc's Net Income?
Net Income
-13.7m
USD
Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's Net Income amounts to -13.7m USD.
What is NeuBase Therapeutics Inc's Net Income growth rate?
Net Income CAGR 10Y
-9%
Over the last year, the Net Income growth was 59%. The average annual Net Income growth rates for NeuBase Therapeutics Inc have been 8% over the past three years , -1% over the past five years , and -9% over the past ten years .
